Reply to: “From NAFLD to MASLD: Promise and pitfalls of a new definition’

• Mary E. Rinella,
• Graciela E.Castro Narro,
• Aleksander Krag,
• Norah Terrault,
• Philip N. Newsome

Affiliations

Mary E. Rinella

University of Chicago, Pritzker School of Medicine, Chicago, IL, USA

Graciela E.Castro Narro

Department of Hepatology and Transplant, Hospital Médica Sur, Mexico City, Mexico; Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico; Asociación Latinoamericana para el Estudio del Hígado (ALEH), Santiago, Chile

Aleksander Krag

Correspondence author at: Department of Gastroenterology and Hepatology, Odense University Hospital, Odense, Denmark.; Department of Gastroenterology and Hepatology, Odense University Hospital, Odense, Denmark; European Association for the Study of the Liver (EASL), Geneva, Switzerland

Norah Terrault

Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; American Association for the Study of Liver Diseases (AASLD), Alexandria, USA

Philip N. Newsome

National Institute for Health Research, Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, Birmingham, UK; Centre for Liver & Gastrointestinal Research, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK